文献速递前列腺癌

转移性前列腺癌的减瘤性前列腺切除术:多中心前瞻性转移性前列腺癌局部治疗(LoMP)试验的初步经验

Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial.
PubMed 文献 · Urology · 2017-04-20

LoMP试验前瞻性评估新诊断转移性前列腺癌患者,比较减瘤性根治性前列腺切除术(cRP)联合标准治疗(SoC)与单纯SoC。cRP组17例,SoC组29例。cRP组手术时间中位215分钟,出血量250 mL,住院4天;3个月内1级和2级并发症分别为5例(29.4%)和2例(11.8%)。cRP组较SoC组更年轻(64 vs 72岁,P=.005),初始PSA更低(15.9 vs 156 µg/L,P=.002),高瘤负荷转移更少(5.9% vs 69%,P<.001)。3个月时cRP组5例(29.4%)报告压力性尿失禁,无其他局部症状;SoC组分别有2例(6.8%)急迫性尿失禁、11例(37.9%)需医疗干预的梗阻性排尿、2例(6.8%)输尿管梗阻。结论:在精选患者中cRP是安全的,这些患者特征更有利;若仅能提供SoC,患者有出现局部症状的风险。

要点

  • cRP组手术时间中位215分钟,出血量250 mL,住院4天
  • cRP组3个月内1级和2级并发症分别为5例(29.4%)和2例(11.8%)
  • cRP组较SoC组更年轻、初始PSA更低、高瘤负荷转移更少

核心结论

  • 在精选患者中,cRP是安全的
  • cRP患者较仅接受SoC的患者具有更有利的特征
  • 若仅能提供SoC,患者有出现局部症状的风险

研究设计与样本

  • LoMP试验为多中心前瞻性试验,评估cRP联合SoC对比单纯SoC
  • cRP组(A组)为无症状、肿瘤可切除且适合手术的患者,n=17
  • SoC组(B组)为不适合或不愿意接受cRP的转移性前列腺癌患者,n=29
  • 术后3个月评估cRP相关手术并发症和两组局部症状

主要发现

  • cRP组手术时间中位215分钟(范围150-290),出血量中位250 mL(范围100-900),住院中位4天(范围2-7)
  • cRP组术后3个月内1级并发症5例(29.4%),2级并发症2例(11.8%)
  • cRP组较SoC组更年轻(64 vs 72岁,P=.005),初始PSA更低(15.9 vs 156 µg/L,P=.002),高瘤负荷转移更少(5.9% vs 69%,P<.001)
  • 3个月时cRP组5例(29.4%)报告压力性尿失禁,无其他局部症状
  • SoC组分别有2例(6.8%)急迫性尿失禁、11例(37.9%)需医疗干预的梗阻性排尿、2例(6.8%)输尿管梗阻

临床怎么用

  • 原文未据此给出推荐

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To prospectively evaluate patients with newly diagnosed metastatic prostate cancer in the context of the LoMP trial (which investigates the role of cytoreductive radical prostatectomy [cRP] in addition to standard of care [SoC]) and to provide a preliminary analysis of patient's characteristics, safety of cRP, and early local symptoms. PATIENTS AND METHODS: cRP was performed in asymptomatic patients with a resectable tumor and who were fit to undergo surgery (group A, n = 17). Only SoC was administered to patients with metastatic prostate cancer ineligible or unwilling to undergo cRP (group B, n = 29). At 3 months, surgical complications related to cRP and local symptoms for both groups were evaluated. RESULTS: Median operation time, blood loss, and hospital stay for cRP were 215 minutes (150-290), 250 mL (100-900), and 4 days (2-7), respectively. Respectively 5 (29.4%) and 2 (11.8%) patients suffered grades 1 and 2 complications within 3 months postoperatively. When compared with Group B, patients in group A were younger (64 vs 72 years, P = .005), had lower initial prostate-specific antigen (15.9 vs 156 µg/L, P = .002), and less high-volume metastatic disease (5.9% vs 69%, P <.001). At 3 months, 5 (29.4%) patients in group A reported stress urinary incontinence without any further local symptoms. In group B, respectively 2 (6.8%), 11 (37.9%), and 2 (6.8%) patients suffered urge incontinence, obstructive voiding needing medical intervention, and ureteric obstruction. CONCLUSION: In a group of well-selected patients, cRP is safe. These patients have more favorable characteristics compared with patients treated with only SoC. If only SoC can be offered, patients are at risk to suffer from local symptoms.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Poelaert F, Verbaeys C, Rappe B, et al. Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. Urology. 2017. PMID: 28435034. doi:10.1016/j.urology.2017.02.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。